van Dijk Elon H C, Dijkman Greet, Theelen Thomas, Hoyng Carel B, Boon Camiel J F
Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Retin Cases Brief Rep. 2018;12(4):266-271. doi: 10.1097/ICB.0000000000000498.
To assess the short-term outcome of and possible temporary vision loss after half-dose verteporfin photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC).
In this prospective study, 14 eyes of 13 cCSC patients who underwent half-dose PDT were included. Patients received spectral-domain optical coherence tomography (OCT) imaging and microperimetry before PDT on the day of treatment and 1 week after treatment.
Five patients (38%) reported worsening of visual complaints in the week after half-dose PDT. No significant changes in both central foveal thickness, height of subretinal fluid, and choroidal thickness on optical coherence tomography imaging and retinal sensitivity on microperimetry were observed, neither in the patients who did not experience worsening of visual symptoms, nor in those who did.
Worsening of visual complaints can occur in a noteworthy number of cCSC patients in the first week after half-dose verteporfin PDT. Despite the fact that no significant short-term changes on both optical coherence tomography and microperimetry have been detected in this study, the assessment could be of importance for the long-term outcome of treatment and needs further investigation.
评估慢性中心性浆液性脉络膜视网膜病变（cCSC）患者接受半剂量维替泊芬光动力疗法（PDT）后的短期疗效及可能出现的暂时性视力丧失情况。
在这项前瞻性研究中，纳入了13例接受半剂量PDT治疗的cCSC患者的14只眼。患者在治疗当天及治疗后1周接受半剂量PDT前进行了光谱域光学相干断层扫描（OCT）成像和微视野检查。
5例患者（38%）报告在半剂量PDT后的一周内视觉症状加重。在未出现视觉症状加重的患者以及出现视觉症状加重的患者中，光学相干断层扫描成像上的中央凹厚度、视网膜下液高度和脉络膜厚度以及微视野检查中的视网膜敏感度均未观察到显著变化。
相当数量的cCSC患者在接受半剂量维替泊芬PDT后的第一周内可能出现视觉症状加重。尽管本研究未检测到光学相干断层扫描和微视野检查在短期内有显著变化，但该评估对于治疗的长期疗效可能具有重要意义，需要进一步研究。
